Cytonics Announces Issuance of US Patent for a Method of Treatment of Chronic Wounds Using Alpha-2-Macroglobulin (A2M) from Whole Blood or a Recombinant Variant of A2M

May 31, 2016

Jupiter, FL: Cytonics Corporation, a biotechnology company focused on the development of biologic therapies for musculoskeletal diseases, today announced that the United States Patent Office issued patent US 9,352,021 covering a method for treating chronic wounds using the naturally occurring A2M molecule. This proprietary technology is being developed to treat chronic inflammation and post-surgery recovery.

Alpha-2-Macroglobulin (A2M) is an abundant, endogenous blood protein that inhibits all classes of serine proteases and metalloproteases, thereby decreasing protein degradation involved in osteoarthritis and attenuating joint pain. Cytonics’ recombinant Alpha-2-Macroglobulin variant, CYT-108, is a synthesized protein that contains a series of mutations within the bait region of the protein structure. The mutated bait region was designed to increase the potency of the A2M molecule, allowing small doses to have large therapeutic effects.J

“Treatments for chronic wounds represent an unmet clinical need, and Cytonics has been able to demonstrate that A2M plays a role in the wound healing process. Chronic wounds are characterized by the body’s inability to heal the wound due to traumatic factors, and a common characteristic of chronic wounds is the elevated activity of a class of proteins known as proteases. We already knew that our A2M technology was capable of inhibiting the proteases that are elevated in osteoarthritis, so applying the therapy to chronic wounds was an obvious extension.”

Gaetano Scuderi, MD
Founder and CEO of Cytonics

About Cytonics:

Cytonics, founded in 2006, is a private research and development company focusing on molecular diagnostic and therapeutic products for chronic musculoskeletal diseases. The company developed the FACT diagnostic test which helps identify the source of back and joint pain and assists physicians in determining the most appropriate treatment. Cleared in January of 2014, Cytonics developed the Autologous Platelet-Integrated Concentrate (APIC) System as a platelet-rich-plasma (PRP) device. In addition, the company also developed autologous cell-free A2M concentrate and other forms of A2M therapeutics, including optimized recombinant forms. The company is currently pursuing pre-clinical studies for their lead recombinant A2M candidate, Cyt-108.

658 W. Indiantown Rd. Suite 214
Jupiter, FL 33458